ATE424386T1 - Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten - Google Patents

Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten

Info

Publication number
ATE424386T1
ATE424386T1 AT05817767T AT05817767T ATE424386T1 AT E424386 T1 ATE424386 T1 AT E424386T1 AT 05817767 T AT05817767 T AT 05817767T AT 05817767 T AT05817767 T AT 05817767T AT E424386 T1 ATE424386 T1 AT E424386T1
Authority
AT
Austria
Prior art keywords
prostaglandin
treatment
mediated diseases
pyridine compounds
pyridine
Prior art date
Application number
AT05817767T
Other languages
English (en)
Inventor
Gerard Giblin
Adrian Hall
David Hurst
Derek Rawlings
Tiziana Scoccitti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35735391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE424386(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0428263A external-priority patent/GB0428263D0/en
Priority claimed from GB0508458A external-priority patent/GB0508458D0/en
Priority claimed from GB0524675A external-priority patent/GB0524675D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE424386T1 publication Critical patent/ATE424386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05817767T 2004-12-23 2005-12-21 Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten ATE424386T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0428263A GB0428263D0 (en) 2004-12-23 2004-12-23 Compounds
GB0508458A GB0508458D0 (en) 2005-04-26 2005-04-26 Compounds
GB0524675A GB0524675D0 (en) 2005-12-02 2005-12-02 Compounds

Publications (1)

Publication Number Publication Date
ATE424386T1 true ATE424386T1 (de) 2009-03-15

Family

ID=35735391

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05817767T ATE424386T1 (de) 2004-12-23 2005-12-21 Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten

Country Status (20)

Country Link
US (2) US20100137378A1 (de)
EP (2) EP2053042A1 (de)
JP (1) JP2008525363A (de)
KR (1) KR20070091301A (de)
AR (1) AR052429A1 (de)
AT (1) ATE424386T1 (de)
AU (1) AU2005318372A1 (de)
BR (1) BRPI0519398A2 (de)
CA (1) CA2592442A1 (de)
DE (1) DE602005013116D1 (de)
EA (2) EA200701324A1 (de)
ES (1) ES2321535T3 (de)
IL (1) IL183781A0 (de)
MA (1) MA29082B1 (de)
MX (1) MX2007007830A (de)
NO (1) NO20073332L (de)
PE (2) PE20060838A1 (de)
TW (1) TW200640865A (de)
UY (1) UY29298A1 (de)
WO (1) WO2006066968A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608825D0 (en) * 2006-05-04 2006-06-14 Glaxo Group Ltd Compounds
CA2687764A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2570125A1 (de) * 2011-09-16 2013-03-20 Almirall, S.A. EP1-Rezeptorliganden
TN2016000542A1 (en) 2014-06-03 2018-04-04 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2021174475A1 (en) * 2020-03-05 2021-09-10 Givaudan Sa Organic compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1471276A (en) 1975-01-22 1977-04-21 Nippon Shinyaku Co Ltd 5-benzylpicolinic acid deri vatives
EP0388682A1 (de) 1989-03-15 1990-09-26 Bayer Ag Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
JPH09507846A (ja) 1993-12-30 1997-08-12 スミスクライン・ビーチャム・コーポレイション フェニルメチルヘキサンアミドおよびその使用
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー．ディー．サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
TW502026B (en) 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US6605624B1 (en) 1998-02-13 2003-08-12 Pharmacia Corporation Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
CA2384783A1 (en) 1999-09-14 2001-03-22 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
CN1659131A (zh) 2002-04-08 2005-08-24 葛兰素集团有限公司 2－((2－烷氧基)－苯基)－环戊－1－烯基)芳香碳－以及杂环羧酸及其衍生物
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
EP1558614B1 (de) 2002-10-30 2010-09-01 Merck Frosst Canada Ltd. Pyridopyrrolizin- und pyridoindolizinderivate
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
GB0306329D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Compounds
GB0323581D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
GB0323585D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323584D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
EP1675832B1 (de) 2003-10-24 2008-02-20 Glaxo Group Limited Heterocyclylverbindungen
GB0328024D0 (en) 2003-12-03 2004-01-07 Glaxo Group Ltd Compounds
GB0410121D0 (en) 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
TW200640865A (en) 2006-12-01
KR20070091301A (ko) 2007-09-10
JP2008525363A (ja) 2008-07-17
EP1833795B1 (de) 2009-03-04
EP2053042A1 (de) 2009-04-29
NO20073332L (no) 2007-09-17
CA2592442A1 (en) 2006-06-29
EA200801909A1 (ru) 2009-06-30
EP1833795A1 (de) 2007-09-19
WO2006066968A1 (en) 2006-06-29
ES2321535T3 (es) 2009-06-08
MX2007007830A (es) 2007-07-25
US20080249138A1 (en) 2008-10-09
BRPI0519398A2 (pt) 2009-01-20
UY29298A1 (es) 2006-05-31
AR052429A1 (es) 2007-03-21
AU2005318372A1 (en) 2006-06-29
EA200701324A1 (ru) 2007-10-26
PE20060838A1 (es) 2006-10-12
IL183781A0 (en) 2007-09-20
MA29082B1 (fr) 2007-12-03
US7759369B2 (en) 2010-07-20
PE20081440A1 (es) 2008-12-31
US20100137378A1 (en) 2010-06-03
DE602005013116D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
DE602005013116D1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
HUE050998T2 (hu) Gyógyszerek fibrotikus betegségek kezelésére
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
DE602005015963D1 (de) Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties